Value of 18F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment

X. Palard-Novello (1) , S. Querellou (1, 2) , M. Gouillou (2) , A. Saraux (3, 4) , T. Marhadour (4) , F. Garrigues (5) , R. Abgral (1, 6) , P. Y. Salaün (1, 2) , V. Devauchelle-Pensec (3, 4)

1 Department of Nuclear Medicine
2 CIC - Brest - Centre d'Investigation Clinique
3 EA2216 - Immunologie et Pathologie
4 CHU - BREST - Rhumato - CHRU Brest - Service de Rhumatologie
5 DR - Brest - Département de radiologie [Brest]
6 GETBO - Groupe d'Etude de la Thrombose de Bretagne Occidentale

Domaines: Immunologie

X. Palard-Novello, S. Querellou, M. Gouillou, A. Saraux, T. Marhadour, et al.. Value of 18F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment. European Journal of Nuclear Medicine and Molecular Imaging, 2016, ⟨10.1007/s00259-015-3287-z⟩. ⟨hal-01270910⟩